Invex Therapeutics (ASX:IXC) EV-to-EBIT : 0.04 (As of May. 12, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Invex Therapeutics's Enterprise Value is A$-0.29 Mil. Invex Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-6.83 Mil. Therefore, Invex Therapeutics's EV-to-EBIT for today is 0.04.

The historical rank and industry rank for Invex Therapeutics's EV-to-EBIT or its related term are showing as below:

ASX:IXC' s EV-to-EBIT Range Over the Past 10 Years
Min: -76.12 Med: 0 Max: 2.89
Current: 0.04

During the past 4 years, the highest EV-to-EBIT of Invex Therapeutics was 2.89. The lowest was -76.12. And the median was 0.00.

ASX:IXC's EV-to-EBIT is ranked better than
95.38% of 433 companies
in the Biotechnology industry
Industry Median: 9.43 vs ASX:IXC: 0.04

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Invex Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was A$-0.06 Mil. Invex Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-6.83 Mil. Invex Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 10,574.48%.

Invex Therapeutics EV-to-EBIT Historical Data

The historical data trend for Invex Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invex Therapeutics EV-to-EBIT Chart

Invex Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

EV-to-EBIT

-18.03

-5.99

-1.85

0.83

Invex Therapeutics Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial				-	-1.85	-	0.83	-

Competitive Comparison of Invex Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Invex Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invex Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's EV-to-EBIT falls into.

Invex Therapeutics EV-to-EBIT Calculation

Invex Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	-0.290	/	-6.825
	=	0.04

Invex Therapeutics's current Enterprise Value is A$-0.29 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Invex Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-6.83 Mil.

Invex Therapeutics (ASX:IXC) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Invex Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-6.825	/	-0.0645422
	=	10,574.48 %

Invex Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was A$-0.06 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Invex Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was A$-6.83 Mil.

Invex Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Invex Therapeutics (ASX:IXC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008

Website

https://www.invextherapeutics.com

Invex Therapeutics Ltd is a biopharmaceutical company, focused on the research and development of Exenatide as a treatment for neurological conditions such as Idiopathic Intracranial Hypertension (IIH), traumatic brain injury, or acute stroke. Its other program under development is Presendin which can be used for disabling headaches and permanent vision loss in females. Geographically, it operates only in Australia.